
AXGT
Healthcare · Biotechnology · $99.2M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2020 | Time not confirmed | -0.29 | -0.21 | +27.6% |
| Aug 11, 2020 | Time not confirmed | -0.44 | -0.20 | +54.5% |
| Jun 10, 2020 | Time not confirmed | -0.58 | -0.54 | +6.9% |
| Feb 10, 2020 | Time not confirmed | -0.67 | -0.62 | +7.5% |
| Nov 8, 2019 | Time not confirmed | -1.09 | -0.61 | +44.0% |
| Aug 9, 2019 | Time not confirmed | -0.91 | -1.23 | -35.2% |
| Jun 11, 2019 | Time not confirmed | -1.70 | -0.45 | +73.5% |
| Feb 7, 2019 | Time not confirmed | -2.08 | -2.16 | -3.8% |
| Nov 7, 2018 | Time not confirmed | -2.92 | -2.24 | +23.3% |
| Aug 7, 2018 | Time not confirmed | -1.47 | -3.84 | -161.2% |
| Jun 11, 2018 | Time not confirmed | -2.91 | -1.84 | +36.8% |
| Feb 9, 2018 | Time not confirmed | -3.97 | -4.32 | -8.8% |
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license…